Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis*
暂无分享,去创建一个
X. Montalban | O. Vitek | E. Sabidó | M. Comabella | C. Chiva | J. Álvarez-cermeño | Meena Choi | E. Borràs | Ester Cantó | Luisa María Villar
[1] À. Rovira,et al. Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis , 2014, Journal of Neuroinflammation.
[2] Brendan MacLean,et al. MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments , 2014, Bioinform..
[3] S. Sadiq,et al. Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status , 2014, Molecular Diagnosis & Therapy.
[4] G. Ingram,et al. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis , 2014, Acta Neuropathologica Communications.
[5] S. Lehmann,et al. Chitinase 3-like 1 and Chitinase 3-like 2 as Diagnostic and Prognostic Biomarkers of Multiple Sclerosis (S53.005) , 2014 .
[6] Nadja Tajouri,et al. Exploring the human tear fluid: Discovery of new biomarkers in multiple sclerosis , 2014, Proteomics. Clinical applications.
[7] H. Weiner,et al. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development , 2014, Multiple sclerosis.
[8] Y. Ishihama,et al. Discovery of Colorectal Cancer Biomarker Candidates by Membrane Proteomic Analysis and Subsequent Verification using Selected Reaction Monitoring (SRM) and Tissue Microarray (TMA) Analysis* , 2014, Molecular & Cellular Proteomics.
[9] E. Rizzarelli,et al. Carnosinases, Their Substrates and Diseases , 2014, Molecules.
[10] R. Aebersold,et al. Targeted protein quantification using sparse reference labeling , 2014, Nature Methods.
[11] Pei Wang,et al. Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins , 2013, Nature Methods.
[12] B. Weinstock-Guttman,et al. Impact of diagnosis and early treatment on the course of multiple sclerosis. , 2013, The American journal of managed care.
[13] A. Prakash,et al. Targeted Selected Reaction Monitoring Mass Spectrometric Immunoassay for Insulin-like Growth Factor 1 , 2013, PloS one.
[14] E. Diamandis,et al. Differential Diagnosis of Azoospermia with Proteomic Biomarkers ECM1 and TEX101 Quantified in Seminal Plasma , 2013, Science Translational Medicine.
[15] X. Montalban,et al. Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis , 2013, Journal of Neuroimmunology.
[16] Y. Shimizu,et al. Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica , 2013, Journal of Neuroimmunology.
[17] M. Fehlings,et al. Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity , 2013, Journal of neurochemistry.
[18] Alessandra Giorgi,et al. Involvement of Oxidative Stress in Occurrence of Relapses in Multiple Sclerosis: The Spectrum of Oxidatively Modified Serum Proteins Detected by Proteomics and Redox Proteomics Analysis , 2013, PloS one.
[19] I. Kockum,et al. Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13 , 2013, Multiple sclerosis.
[20] T. Olsson,et al. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity , 2013, Proceedings of the National Academy of Sciences.
[21] Y. Zhang,et al. Soluble CD146 in cerebrospinal fluid of active multiple sclerosis , 2013, Neuroscience.
[22] D. Centonze,et al. Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis , 2013, Proteomics.
[23] T. Olsson,et al. Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. , 2013, Journal of proteome research.
[24] C. Vedeler,et al. Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. , 2013, Journal of proteomics.
[25] S. Carr,et al. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry , 2013, Nature Methods.
[26] W. LaFramboise,et al. Exacerbation of Experimental Autoimmune Encephalomyelitis in the Absence of Breast Regression Protein 39/Chitinase 3-Like 1 , 2012, Journal of neuropathology and experimental neurology.
[27] Ruedi Aebersold,et al. Reproducible Quantification of Cancer-Associated Proteins in Body Fluids Using Targeted Proteomics , 2012, Science Translational Medicine.
[28] F. Matesanz,et al. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis , 2012, Multiple sclerosis.
[29] A. Salinaro,et al. Administration of carnosine in the treatment of acute spinal cord injury. , 2011, Biochemical pharmacology.
[30] Ariel Miller,et al. Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis , 2011, Journal of cellular and molecular medicine.
[31] P. Hluštík,et al. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome , 2011, Neurological research.
[32] B. Ma,et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. , 2011, Annual review of physiology.
[33] G. Ingram,et al. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. , 2010, Brain : a journal of neurology.
[34] T. Olsson,et al. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. , 2010, Journal of proteomics.
[35] À. Rovira,et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. , 2010, Brain : a journal of neurology.
[36] J. Losek,et al. Anisocoria and Topical Carbamate Exposure: Illustrative Case Report , 2010, Clinical pediatrics.
[37] M. Milazzo,et al. Protein expression profiles in pediatric multiple sclerosis: potential biomarkers , 2009, Multiple sclerosis.
[38] A. Rovira,et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? , 2008, Neurology.
[39] A. Thompson,et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. , 2008, Brain : a journal of neurology.
[40] À. Rovira,et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes , 2006, Neurology.
[41] P. Ruzza,et al. Carnosine and carnosine-related antioxidants: a review. , 2005, Current medicinal chemistry.
[42] A. Thompson,et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis , 2005, The Lancet Neurology.
[43] Y. Sei,et al. Isoprinosine-induced modulation of T-helper-cell subsets and antigen-presenting monocytes (Leu M3 + Ia +) resulted in improvement of T- and B-lymphocyte functions, in vitro in ARC and AIDS patients. , 1987, Clinical immunology and immunopathology.
[44] J. Mussini,et al. [Immunology of multiple sclerosis]. , 1982, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.